Outlook Therapeutics appoints Laura Cantrell as VP of Corporate Strategy and Business Development to enhance business initiatives.
Quiver AI Summary
Outlook Therapeutics, Inc. has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development to help advance the company's mission to enhance the treatment of retina diseases with its ophthalmic formulation of bevacizumab, known as LYTENAVA™. CEO Bob Jahr expressed confidence that Cantrell's extensive experience in biotechnology, particularly in corporate strategy and business development, will be crucial as the company seeks strategic partnerships and licensing opportunities. Cantrell joins Outlook with over 20 years of industry experience, having held senior roles at notable biotechnology firms and being involved in significant licensing and acquisition efforts. Outlook Therapeutics is currently launching LYTENAVA™ in Germany and the UK for wet AMD, while the product is still under investigation in the United States.
Potential Positives
- Appointment of Laura Cantrell as Vice President of Corporate Strategy and Business Development, bringing over 20 years of experience and expertise in the biotechnology and pharmaceutical industries.
- Her experience includes key leadership roles in significant biopharmaceutical companies and successful high-impact initiatives, which could enhance Outlook Therapeutics' strategic opportunities and business growth.
- Outlook Therapeutics has commenced the commercial launch of LYTENAVA™ in Germany and the UK, signaling progress in its mission to enhance the standard of care for retinal diseases.
- If approved in the United States, ONS-5010/LYTENAVA™ would represent a significant advancement as the first approved ophthalmic formulation of bevacizumab for retinal indications, potentially increasing market access and revenue opportunities.
Potential Negatives
- Appointment of a new Vice President of Corporate Strategy and Business Development could indicate a need for strategic overhaul, potentially signaling previous challenges in corporate direction or execution.
- The press release emphasizes the significance of the role and timing of the new appointment, which may highlight existing gaps in leadership or strategy that the company seeks to address.
- The U.S. market approval for ONS-5010/LYTENAVA™ remains in investigational status, indicating uncertainty in achieving commercialization and potential missed revenue opportunities compared to its European launch.
FAQ
Who is Laura Cantrell?
Laura Cantrell is the newly appointed Vice President of Corporate Strategy and Business Development at Outlook Therapeutics.
What is Outlook Therapeutics focused on?
Outlook Therapeutics focuses on enhancing the standard of care for bevacizumab in treating retina diseases.
What is LYTENAVA™?
LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab approved for wet AMD in Europe.
What role will Laura Cantrell play at Outlook Therapeutics?
Laura Cantrell will lead the company’s business development strategy, including partnerships and licensing opportunities.
What is ONS-5010?
ONS-5010 is an investigational drug, an ophthalmic formulation of bevacizumab aimed at retinal indications in the U.S.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OTLK Revenue
$OTLK had revenues of $-92.3K in Q4 2025.
You can track OTLK financials on Quiver Quantitative's OTLK stock page.
$OTLK Hedge Fund Activity
We have seen 19 institutional investors add shares of $OTLK stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SCHONFELD STRATEGIC ADVISORS LLC removed 649,639 shares (-47.6%) from their portfolio in Q3 2025, for an estimated $688,617
- MORGAN STANLEY removed 424,824 shares (-99.8%) from their portfolio in Q3 2025, for an estimated $450,313
- STEWARD PARTNERS INVESTMENT ADVISORY, LLC removed 366,187 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $388,158
- FMR LLC removed 170,396 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $180,619
- SQUAREPOINT OPS LLC removed 155,624 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $164,961
- MILLENNIUM MANAGEMENT LLC removed 143,988 shares (-42.5%) from their portfolio in Q3 2025, for an estimated $152,627
- RENAISSANCE TECHNOLOGIES LLC removed 106,068 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $112,432
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OTLK Analyst Ratings
Wall Street analysts have issued reports on $OTLK in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 12/22/2025
To track analyst ratings and price targets for $OTLK, check out Quiver Quantitative's $OTLK forecast page.
$OTLK Price Targets
Multiple analysts have issued price targets for $OTLK recently. We have seen 3 analysts offer price targets for $OTLK in the last 6 months, with a median target of $1.0.
Here are some recent targets:
- Daniil Gataulin from Chardan Capital set a target price of $1.0 on 01/05/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $0.5 on 01/02/2026
- Edward Woo from Ascendiant Capital set a target price of $10.0 on 12/22/2025
Full Release
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development.
“We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Laura’s two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value opportunities, will be instrumental as we advance our mission to deliver a differentiated ophthalmic formulation of bevacizumab and pursue opportunities to maximize long-term shareholder value.”
In her role as Vice President of Corporate Strategy and Business Development, Ms. Cantrell will be responsible for leading Outlook Therapeutics’ business development strategy, including strategic partnerships, licensing opportunities and corporate development initiatives.
“I am excited to join Outlook Therapeutics and to work alongside the leadership team at such an important moment for the Company,” said Laura Cantrell, newly appointed Vice President of Corporate Strategy and Business Development. “I look forward to leveraging my experience in business development, global partnerships and portfolio strategy to help advance the company’s programs, explore strategic opportunities and support Outlook’s next phase of growth.”
Ms. Cantrell brings more than 20 years of experience in global corporate strategy, business development, and portfolio leadership across the biotechnology and pharmaceutical industries and is a seasoned biotech executive with deep expertise in business development, commercial strategy, and global portfolio expansion. She has held senior leadership roles at leading biotechnology companies, including Medivation (acquired by Pfizer), BeiGene, Sobi, Axovant Sciences, and Genentech/Roche. During her career, she has led high-impact licensing, acquisition, and partnership initiatives, including serving as a core member of the team that supported Medivation’s $14 billion acquisition by Pfizer and the commercial assessment supporting the acquisition of TALZENNA. Ms. Cantrell has extensive experience driving global commercialization strategies and lifecycle management for biologics and oncology assets, including bevacizumab, and has led asset teams responsible for launches and regulatory approvals across North America, Europe, and international markets. Ms. Cantrell holds an MBA from Emory University and a Bachelor of Science in Biology from the University of Michigan.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics has commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f664cc57-e281-4cc3-a237-5e19e88648ea
